Artal Group S.A. Abb Vie Inc. Call Options Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $81.8 Million - $90.1 Million	-800,000 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $24.1 Million - $32.6 Million	300,000 Added 60.0%	800,000 $85.7 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $21.5 Million - $25.2 Million	250,000 Added 100.0%	500,000 $43.8 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $18.3 Million - $24.5 Million	250,000 New	250,000 $24.5 Million

3,653

1.24B

15.5M

11.6M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $290B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.